A User Guide To FDA's
Orphan Drugs: Understanding the FDA Approval Process
CDER 21st Century Review Desk Reference Guide
Frontiers | A Regulatory Risk-Based Approach to ATMP/CGT Development: Integrating Scientific Challenges With Current Regulatory Expectations
CMC-Related Technical and Regulatory Aspects for Development of Biotherapeutic Products
A detailed analysis of expedited regulatory review time of marketing authorization applications for new anticancer drugs in the US and EU - da Costa Gonçalves - 2022 - Clinical and Translational Science - Wiley Online Library
Overview of FDA Expedited Development and Approval Programs for Serious Conditions - SYNER-G
Rolling Reviews During COVID-19: The European Union Experience in a Global Context - ScienceDirect
Accelerated Change: Understanding the FDA's Expedited Pathways
CytoDyn submits the first section of HIV BLA to FDA under rolling review | Seeking Alpha
FDA's Framework for Regulating Regenerative Medicine Will Improve Oversight | The Pew Charitable Trusts
FDA's Expedited Review Process: The Need for Speed
Eli Lilly gets FDA's speedy review for obesity drug | Reuters
CorMedix eyes US FDA priority review for bloodstream infection drug Defencath | S&P Global Market Intelligence
FDA Expedited Review Programs - Friends of Cancer Research
How to Expedite Drug Approval | RegDesk | Professional software
Lumicell's LUM Imaging System for Breast Cancer Wins FDA Fast Track
Summary of FDA Expedited Development and Review Programs. | Download Scientific Diagram
The Need for Speed in Drug Development: A Sponsor's Guide to FDA Expedited Programs | Halloran Consulting Group
Accelerate Your Review with Rolling NDA & BLA Submissions
Vertex/CRISPR to begin rolling review in US for gene-edited therapy; get FDA designations | Seeking Alpha
FDA's Expedited Review Process: The Need for Speed
The Science Of A Biotech Valuation: How To Interpret The Value Of FDA Expedited Programs (NASDAQ:IBB) | Seeking Alpha
Expediting Drug Development — The FDA's New “Breakthrough Therapy” Designation | NEJM
CytoDyn Inc. submits the first of three main sections of its HIV Biologics License Application to FDA under rolling review
Analysis of the Real-Time Oncology Review (RTOR) Pilot Program for Approvals of New Molecular Entities | SpringerLink
